Astellas Pharma Europe, a European subsidiary of Astellas, has introduced Dificlir (generic name: fidaxomicin) tablets in the Europe. Dificlir, indicated to treat Clostridium difficile infections (CDI), is an orally administered, ...
Tags: Dificlir, fidaxomicin, CDI
Medivation and Astellas Pharma have launched Xtandi (enzalutamide) capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Xtandi, an oral, once-daily androgen receptor inhibitor ...
AVEO Oncology and Astellas Pharma have announced FDA acceptance of tivozanib new drug application(NDA)filing for the treatment of advanced renal cell carcinoma(RCC). According to the development and commercialization deal signed between ...
Tags: AVEO Oncology, Astellas Pharma, FDA, RCC, NDA
Janssen Biotech has signed a license agreement with Astellas Pharma for the worldwide development and commercialization of ASP015K, except in Japan. Astellas will continue development and commercialization of ASP015K in Japan. ASP015K, ...
Tags: Janssen Biotech, Astellas Pharma, license agreement, ASP015K
Astellas Pharma's Gonax drug used in the treatment of prostate cancer, has been awarded marketing rights in Japan. Based on the positive results from phase I, II studies in Japan and phase III studies in abroad, Astellas has applied for ...
Astellas Pharma has announced the market launch of Quattrovac subcutaneous injection syringe, the combined vaccine indicated for pertussis, diphtheria, tetanus and poliomyelitis, in Japan. The vaccine was manufactured by ...
Tags: Astellas Pharma, Quattrovac Subcutaneous Injection, combined vaccine
Astellas Pharma has introduced Gonax (Degarelix Acetate), a gonadotrophin-releasing hormone (GnRH)-receptor blocker, for subcutaneous injection to treat prostate cancer in Japan. Gonax is designed to inhibit the binding of GnRH, a hormone ...
Astellas Pharma and AstraZeneca have announced the approval of the dry-power inhaler Symbicort Turbuhaler for the additional indication of chronic obstructive pulmonary disease(COPD). Symbicort Turbuhaler is a combination product ...
Tags: Astellas Pharma, AstraZeneca, dry-power inhaler Symbicort Turbuhaler
Astellas Pharma and XenoPort have announced the introduction of Regnite (gabapentin enacarbil) extended-release tablets in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS). Regnite, which was discovered ...
Tags: Rls Drug, Restless legs syndrome, Regnite extended-release tablets
Astellas Pharma, a Japan-based pharmaceutical company, has announced its decision to shut down one of its subsidiaries, Urogenix, which is a research facility focusing on drug discovery in the field of urology. The company expects to ...
Tags: urology research, resource allocation, clinical potential
TI Pharma, Merck KGaA, Astellas Pharma and the Swiss Tropical and Public Health Institute (Swiss TPH) have entered into an international public-private partnership (PPP) to develop new pediatric formulation of praziquantel for the treatment ...
Tags: Pediatric Formulation, Swiss TPH, treatment of schistosomiasis
Astellas Pharma and Medivation have announced the submission of marketing authorization application (MAA) to the European Medicines Agency (EMA) for enzalutamide to treat metastatic castration-resistant prostate cancer in men who have ...
Tags: enzalutamide, metastatic castration-resistant prostate cancer
Astellas Pharma has gained FDA approval for Myrbetriq (mirabegron) extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Myrbetriq is a once ...
Tags: FDA approval, pharmaceutical product, oral OAB treatment
Medivation and Astellas Pharma have announced the submission of new drug application (NDA) for enzalutamide (formerly MDV3100) to the FDA. The enzalutamide has been studied in patients with castration-resistant prostate cancer who ...
Tags: enzalutamide, new drug application, pharmaceutical product
Astellas Pharma has announced favorable US court ruling in patent infringement case for OSI Pharmaceuticals, Genentech, a member of the Roche Group, and Pfizer. The US District Court for the District of Delaware has found both the patents ...
Tags: Astellas Pharma, Mylan, lawsuit